Drug Profile
Research programme: respiratory syncytial virus vaccine - Codevax
Alternative Names: RSV vaccineLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Codevax
- Developer Codevax; University of Rochester
- Class Viral vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)
- 16 Jul 2010 Preclinical trials in Respiratory syncytial virus infections in USA (Parenteral)